NMO SPOTLIGHT Registry: Real-World Clinical Outcomes With Eculizumab and Ravulizumab in Anti-Aquaporin-4 Antibody-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) (P11-8.013)
To describe the initial characteristics and clinical outcomes of Registry participants with AQP4-Ab+ NMOSD treated with eculizumab or ravulizumab in real-world clinical practice.
Authors
- Ahmed Z. Obeidat (ORCID: https://orcid.org/0000-0002-3549-3277)
- Sami Fam
- Verónica Tkachuk
- Elias S. Sotirchos (ORCID: https://orcid.org/0000-0002-8812-1637)
- Ho Jin Kim (ORCID: https://orcid.org/0000-0002-8672-8419)
- Lindsey Przybyl
Institutions
- Johns Hopkins University (US)
- Medical College of Wisconsin (US)
- Johns Hopkins Medicine (US)
- Instituto de Diagnóstico e Investigaciones Metabólicas (AR)
- AstraZeneca (Brazil) (BR)
- College Station Medical Center (US)
- Alexion Pharma (Switzerland) (CH)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208776
- Citations
- 1
- Primary Topic
- Protein Tyrosine Phosphatases
- Type
- article
- Field-Weighted Citation Impact
- 0.81